Antibody Germline Characterization of Cross-neutralizing Human IgGs Against 4 Serotypes of Dengue Virus

Overview

Journal Biochem Biophys Res Commun

Publisher Elsevier

Specialty Biochemistry

Date 2014 Mar 19

PMID 24637211

Citations 4

Authors

Pannamthip Pitaksajjakul

Surachet Benjathummarak

Chonlatip Pipattanaboon

Waranya Wongwit

Tamaki Okabayashi

Motoki Kuhara

Ryo Misaki

Kazuhito Fujiyama

Pongrama Ramasoota

Affiliations

Soon will be listed here.

Abstract

Dengue virus (DENV), a re-emerging virus, constitutes the largest vector-borne disease virus, with 50-100 million cases reported every year. Although DENV infection induces lifelong immunity against viruses of the same serotypes, the subsequent infection with the heterologous serotypes can cause more severe form of the disease, such as Dengue Haemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS). However, there is neither approved vaccine nor specific drugs available to treat this disease. In this study, previously developed 19 human monoclonal antibodies (HuMAbs) showing strong to moderate cross neutralizing activity were selected. Most of them (13/19) were targeted to domain II of envelop glycoprotein. To understand and clarify the recognition properties, the maturation mechanisms comprising Variable/Diversity/Joining (VDJ) recombination, Variable Heavy (VH)/Variable Light (VL) chain pairing, variability at junctional site, and somatic hypermutation (SHM) of those antibodies were studied and compared with their predecessor germline sequences. IMGT/V-QUEST database was applied to analyze the isolated VH and VL sequences. To confirm the correction of isolated VH/VL, 3 HuMAbs (1A10H7, 1B3B9, 1G7C2) was transiently expressed in HEK293T cell. All three clones of the expressed recombinant IgG (rIgG) showed the same binding and neutralizing activity as same as those from hybridomas. The data obtained in this study will elucidate the properties of those HuMAbs for further genetic modification, and its binding epitopes.

Citing Articles

Machine-learning-assisted high-throughput identification of potent and stable neutralizing antibodies against all four dengue virus serotypes.

Natsrita P, Charoenkwan P, Shoombuatong W, Mahalapbutr P, Faksri K, Chareonsudjai S Sci Rep. 2024; 14(1):17165.

PMID: 39060292 PMC: 11282219. DOI: 10.1038/s41598-024-67487-8.

as a potential source for producing anti-dengue virus D54 neutralizing therapeutic antibody.

Krittanai S, Rattanapisit K, Bulaon C, Pitaksajjakul P, Keadsanti S, Ramasoota P Biotechnol Rep (Amst). 2024; 42:e00844.

PMID: 38881650 PMC: 11179242. DOI: 10.1016/j.btre.2024.e00844.

Cross-reactive antibodies targeting surface-exposed non-structural protein 1 (NS1) of dengue virus-infected cells recognize epitopes on the spaghetti loop of the β-ladder domain.

Kraivong R, Traewachiwiphak S, Nilchan N, Tangthawornchaikul N, Pornmun N, Poraha R PLoS One. 2022; 17(5):e0266136.

PMID: 35617160 PMC: 9135231. DOI: 10.1371/journal.pone.0266136.

Generation and characterization of cross neutralizing human monoclonal antibody against 4 serotypes of dengue virus without enhancing activity.

Injampa S, Muenngern N, Pipattanaboon C, Benjathummarak S, Boonha K, Hananantachai H PeerJ. 2017; 5:e4021.

PMID: 29152418 PMC: 5689018. DOI: 10.7717/peerj.4021.

References

Marasco W, Sui J . The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol. 2007; 25(12):1421-34. PMC: 7097443. DOI: 10.1038/nbt1363. View

Giudicelli V, Duroux P, Ginestoux C, Folch G, Jabado-Michaloud J, Chaume D . IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T cell receptor nucleotide sequences. Nucleic Acids Res. 2005; 34(Database issue):D781-4. PMC: 1347451. DOI: 10.1093/nar/gkj088. View

Sukupolvi-Petty S, Austin S, Engle M, Brien J, Dowd K, Williams K . Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol. 2010; 84(18):9227-39. PMC: 2937608. DOI: 10.1128/JVI.01087-10. View

He R, Innis B, Nisalak A, Usawattanakul W, Wang S, Kalayanarooj S . Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J Med Virol. 1995; 45(4):451-61. DOI: 10.1002/jmv.1890450417. View

Crill W, Roehrig J . Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol. 2001; 75(16):7769-73. PMC: 115016. DOI: 10.1128/JVI.75.16.7769-7773.2001. View

Chen W, Prabakaran P, Zhu Z, Feng Y, Streaker E, Dimitrov D . Characterization of human IgG repertoires in an acute HIV-1 infection. Exp Mol Pathol. 2012; 93(3):399-407. PMC: 3663482. DOI: 10.1016/j.yexmp.2012.09.022. View

de Alwis R, Smith S, Olivarez N, Messer W, Huynh J, Wahala W . Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A. 2012; 109(19):7439-44. PMC: 3358852. DOI: 10.1073/pnas.1200566109. View

Setthapramote C, Sasaki T, Puiprom O, Limkittikul K, Pitaksajjakul P, Pipattanaboon C . Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection. Biochem Biophys Res Commun. 2012; 423(4):867-72. DOI: 10.1016/j.bbrc.2012.06.057. View

Murrell S, Wu S, Butler M . Review of dengue virus and the development of a vaccine. Biotechnol Adv. 2010; 29(2):239-47. DOI: 10.1016/j.biotechadv.2010.11.008. View

10.

Lin H, Tsai W, Liu I, Li P, Liao M, Tsai J . Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis. 2012; 6(1):e1447. PMC: 3250511. DOI: 10.1371/journal.pntd.0001447. View

11.

Sui J, Hwang W, Perez S, Wei G, Aird D, Chen L . Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009; 16(3):265-73. PMC: 2692245. DOI: 10.1038/nsmb.1566. View

12.

Brochet X, Lefranc M, Giudicelli V . IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008; 36(Web Server issue):W503-8. PMC: 2447746. DOI: 10.1093/nar/gkn316. View

13.

Qi R, Zhang L, Chi C . Biological characteristics of dengue virus and potential targets for drug design. Acta Biochim Biophys Sin (Shanghai). 2008; 40(2):91-101. DOI: 10.1111/j.1745-7270.2008.00382.x. View

14.

Prabakaran P, Zhu Z, Chen W, Gong R, Feng Y, Streaker E . Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Front Microbiol. 2012; 3:277. PMC: 3410596. DOI: 10.3389/fmicb.2012.00277. View

15.

Lingwood D, McTamney P, Yassine H, Whittle J, Guo X, Boyington J . Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature. 2012; 489(7417):566-70. PMC: 7095019. DOI: 10.1038/nature11371. View

16.

Chen W, Streaker E, Russ D, Feng Y, Prabakaran P, Dimitrov D . Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens. Biochem Biophys Res Commun. 2012; 417(4):1164-9. PMC: 3268823. DOI: 10.1016/j.bbrc.2011.12.089. View

17.

Beltramello M, Williams K, Simmons C, Macagno A, Simonelli L, Quyen N . The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010; 8(3):271-83. PMC: 3884547. DOI: 10.1016/j.chom.2010.08.007. View

18.

Sasaki T, Setthapramote C, Kurosu T, Nishimura M, Asai A, Omokoko M . Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection. Antiviral Res. 2013; 98(3):423-31. DOI: 10.1016/j.antiviral.2013.03.018. View

19.

Clyde K, Kyle J, Harris E . Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol. 2006; 80(23):11418-31. PMC: 1642597. DOI: 10.1128/JVI.01257-06. View

20.

Bedouelle H, Belkadi L, England P, Guijarro J, Lisova O, Urvoas A . Diversity and junction residues as hotspots of binding energy in an antibody neutralizing the dengue virus. FEBS J. 2005; 273(1):34-46. DOI: 10.1111/j.1742-4658.2005.05045.x. View